title: Thymoglobulin and rate of infectious complications after transplantation.
abstract: Thymoglobulin is used as an induction agent in kidney transplantation, but the optimal dose is not well established. However, its use may be associated with increased infectious complications after transplantation.
  
  
  METHODS
  This retrospective study of 61 high-risk renal recipients of transplants from deceased donors performed between June 2001 and April 2004 included patients treated with thymoglobulin. Patients were divided into two groups according to the total thymoglobulin dose (G1, n = 30, <7 mg/kg; G2, n = 31, >7 mg/kg) and followed for at least 1 year.
  
  
  RESULTS
  Mean recipient age was 43 +/- 14 years; 41% were males; 63% non-Whites. Mean cold ischemia time was 26.3 +/- 7 hours. Mean PRA was 23% (0-100%). Second transplantation was performed in 18 (29.5%) patients. Mean donor age was 42.1 +/- 16 years, and 59% had a cerebral vascular accident as the cause of death. Patient- and death-censored graft survival at 12 months were 86% and 88%, respectively. There were 149 infectious episodes among 47 (78%) patients. The incidence of infection was 1.7 +/- 0.24 infections per patient per year in G1 (lower dose) vs 3.12 +/- 0.23 in G2 (P < .001). Bacterial (0.66 +/- 1.0 vs 1.48 +/- 1.26 infections per patient per year, P = .009) and viral infections (0.9 +/- 0.71 vs 1.41 +/- 0.71; P = .006) were more frequent in the higher dose group.
  
  
  CONCLUSIONS
  This study suggested that a greater number of infectious episodes were present when the total dose of thymoglobulin was higher than 7 mg/kg.
authors.affiliation: Hospital do Rim e Hipertensao - Nephrology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
authors.forename: P
authors.initials: P
authors.lastname: Clesca
authors.forename: M
authors.initials: M
authors.lastname: Dirlando
authors.forename: S-I
authors.initials: SI
authors.lastname: Park
authors.forename: R
authors.initials: R
authors.lastname: García
authors.forename: E
authors.initials: E
authors.lastname: Ferraz
authors.forename: P G
authors.initials: PG
authors.lastname: Pinheiro-Machado
authors.forename: L
authors.initials: L
authors.lastname: Kushnaroff
authors.forename: H
authors.initials: H
authors.lastname: Tedesco-Silva
authors.forename: J O
authors.initials: JO
authors.lastname: Medina-Pestana
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood*; D000961:Antilymphocyte Serum; D002102:Cadaver; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007239:Infections / Q000453:epidemiology*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology*; D012189:Retrospective Studies; D014019:Tissue Donors
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; C512542:thymoglobulin